Suppr超能文献

决定肢端肥大症手术长期疗效的因素。

Factors determining the long-term outcome of surgery for acromegaly.

作者信息

Osman I A, James R A, Chatterjee S, Mathias D, Kendall-Taylor P

机构信息

Department of Medicine, University of Newcastle upon Tyne, UK.

出版信息

QJM. 1994 Oct;87(10):617-23.

PMID:7987657
Abstract

Seventy-nine patients with acromegaly were investigated before and after transsphenoidal adenomectomy, to determine the immediate and late outcome, the pre-operative features associated with a good result, and the accuracy of post-operative testing in predicting outcome. Pre-operative evaluation included basal growth hormone (GH), GH response to oral glucose tolerance test (OGTT), GH response to thyrotrophin-releasing hormone (TRH), tests of pituitary reserve, and pituitary scanning to assess tumour size. A few weeks after surgery, these tests were repeated. The patients were recalled for late assessment 1-13 years (median 86 months) after the operation. At the immediate postoperative testing, minimum GH after oral glucose was < or = 2 mU/l in 48.7%, < 5 mU/l in 76.3% and < 10 mU/l in 84.2%. Only 12 patients had GH > 10 mU/l. Basal GH was < or = 2 mU/l in 21%, < 5 in 59.2%, < 10 in 73.6% and < 20 in 90.8%. A minimum GH of < or = 2 mU/l during an OGTT was achieved in 67.4% of patients with intrasellar tumours, compared with 27.3% with extrasellar tumours. Basal GH and post-glucose GH correlated with the late outcome. GH response to TRH showed no correlation with outcome. IGF-1, which could not be assessed in detail, correlated with GH but was not a reliable indicator of outcome. Transsphenoidal adenomectomy is thus a very satisfactory treatment for acromegaly. Postoperative levels of basal growth hormone < 5 mU/l and post-glucose GH < or = 2 mU/l can be regarded as a biochemical cure. Postoperative radiotherapy is not required in patients who achieve a good result. The preoperative factors which significantly influenced the final outcome were basal GH, post-glucose minimum GH, tumour size and impaired pituitary reserve.

摘要

对79例肢端肥大症患者在经蝶窦腺瘤切除术前及术后进行了调查,以确定近期和远期疗效、与良好疗效相关的术前特征,以及术后检测在预测疗效方面的准确性。术前评估包括基础生长激素(GH)、GH对口服葡萄糖耐量试验(OGTT)的反应、GH对促甲状腺激素释放激素(TRH)的反应、垂体储备功能测试以及垂体扫描以评估肿瘤大小。术后几周重复这些测试。术后1至13年(中位时间86个月)对患者进行远期评估召回。在术后即刻检测中,口服葡萄糖后最低GH≤2 mU/L的患者占48.7%,<5 mU/L的占76.3%,<10 mU/L的占84.2%。只有12例患者的GH>10 mU/L。基础GH≤2 mU/L的患者占21%,<5 mU/L的占59.2%,<10 mU/L的占73.6%,<20 mU/L的占90.8%。鞍内肿瘤患者中67.4%在OGTT期间最低GH≤2 mU/L,而鞍外肿瘤患者为27.3%。基础GH和葡萄糖后GH与远期疗效相关。GH对TRH的反应与疗效无关。无法详细评估的胰岛素样生长因子-1(IGF-1)与GH相关,但不是疗效的可靠指标。因此,经蝶窦腺瘤切除术是治疗肢端肥大症非常令人满意的方法。术后基础生长激素水平<5 mU/L且葡萄糖后GH≤2 mU/L可视为生化治愈。疗效良好的患者无需术后放疗。显著影响最终疗效的术前因素是基础GH、葡萄糖后最低GH、肿瘤大小和垂体储备功能受损。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验